Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetics and Molecular Pathology, |
RCV002272665 | SCV002556639 | uncertain significance | Platelet-type bleeding disorder 16 | 2020-07-31 | criteria provided, single submitter | clinical testing | 1 xPM2 |
Ambry Genetics | RCV003096131 | SCV003540493 | uncertain significance | Inborn genetic diseases | 2021-08-23 | criteria provided, single submitter | clinical testing | The c.2198C>T (p.A733V) alteration is located in exon 22 (coding exon 22) of the ITGA2B gene. This alteration results from a C to T substitution at nucleotide position 2198, causing the alanine (A) at amino acid position 733 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003605781 | SCV004550327 | uncertain significance | Glanzmann thrombasthenia | 2023-01-25 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 733 of the ITGA2B protein (p.Ala733Val). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ITGA2B protein function. ClinVar contains an entry for this variant (Variation ID: 1698808). This variant has not been reported in the literature in individuals affected with ITGA2B-related conditions. This variant is present in population databases (rs201042087, gnomAD 0.008%). |